Intended for healthcare professionals

CCBYNC Open access
Corrections

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study

BMJ 2023; 380 doi: https://doi.org/10.1136/bmj.p587 (Published 14 March 2023) Cite this as: BMJ 2023;380:p587

In this paper by Lalani and colleagues (BMJ 2023;380:e073747, doi:10.1136/bmj-2022-073747, published 1 March 2023), a transcription error before submission led to inconsistency between the text under “Pandemic funding” relating to the amounts of money received by Moderna and Pfizer-BioNTech and the supplementary data presented in eTable 4. The relevant sentences should now read: “Moderna received $10.8bn, of which $8.8bn (81%) was for vaccine supply. Pfizer-BioNTech received $20.4bn, mostly for vaccine supply.”

The data are accurate, and the text has now been corrected.

http://creativecommons.org/licenses/by-nc/4.0/

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.